Targeting helminths: The expanding world of type 2 immune effector mechanisms.

Authors:
Maizels RM; Gause WC.

Journal:
J Exp Med

Publication Year: 2023

DOI:
10.1084/jem.20221381

PMCID:
PMC10460967

PMID:
37638887

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Exp Med

Abbreviation: J Exp Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Addendum: Resolvins suppress tumor growth and enhance cancer therapy.
Sulciner ML; Serhan CN; Gilligan MM and 18 more (2024) - Transparency Score: 2/6
Anti-PD-1 therapy triggers Tfh cell-dependent IL-4 release to boost CD8 T cell responses in tumor-d…
Ruggiu M; Guérin MV; Corre B and 9 more (2024) - Transparency Score: 3/6
Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children.
Bastard P; Gervais A; Taniguchi M and 87 more (2024) - Transparency Score: 3/6
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy.
Wang L; Xiao Y; Luo Y and 19 more (2024) - Transparency Score: 5/6
The effector program of human CD8 T cells supports tissue remodeling.
Delacher M; Schmidleithner L; Simon M and 32 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosures: W.C. Gause reported patent number 20180207206 licensed. No other disclosures were reported."

Evidence found in paper:

"The authors’ work is supported by R.M. Maizels through a Wellcome Trust Investigator Award (Ref 219530), the Wellcome Trust core-funded Wellcome Centre for Integrative Parasitology (Ref: 104111), and the Netherlands Lung Foundation (Ref: AWWA); and by W.C. Gause through National Institute of Health grants R01DK113790, R01DK113790, and R01AI131634."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025